KR102301463B1 - 사이토메갈로바이러스의 치료를 위한 조성물 및 방법 - Google Patents

사이토메갈로바이러스의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102301463B1
KR102301463B1 KR1020147015909A KR20147015909A KR102301463B1 KR 102301463 B1 KR102301463 B1 KR 102301463B1 KR 1020147015909 A KR1020147015909 A KR 1020147015909A KR 20147015909 A KR20147015909 A KR 20147015909A KR 102301463 B1 KR102301463 B1 KR 102301463B1
Authority
KR
South Korea
Prior art keywords
delete delete
virus
polypeptide
seq
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147015909A
Other languages
English (en)
Korean (ko)
Other versions
KR20140095556A (ko
Inventor
데이비드 이. 앤더슨
안느-까뜨린느 플뤼키거
Original Assignee
배리에이션 바이오테크놀로지스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 배리에이션 바이오테크놀로지스 아이엔씨. filed Critical 배리에이션 바이오테크놀로지스 아이엔씨.
Priority to KR1020197025818A priority Critical patent/KR102340558B1/ko
Publication of KR20140095556A publication Critical patent/KR20140095556A/ko
Application granted granted Critical
Publication of KR102301463B1 publication Critical patent/KR102301463B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
KR1020147015909A 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법 Active KR102301463B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020197025818A KR102340558B1 (ko) 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161558800P 2011-11-11 2011-11-11
US61/558,800 2011-11-11
US201261654157P 2012-06-01 2012-06-01
US61/654,157 2012-06-01
PCT/IB2012/002854 WO2013068847A2 (en) 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197025818A Division KR102340558B1 (ko) 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20140095556A KR20140095556A (ko) 2014-08-01
KR102301463B1 true KR102301463B1 (ko) 2021-09-14

Family

ID=48290708

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147015909A Active KR102301463B1 (ko) 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법
KR1020197025818A Active KR102340558B1 (ko) 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197025818A Active KR102340558B1 (ko) 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법

Country Status (14)

Country Link
US (3) US9777043B2 (enExample)
EP (2) EP2776567B1 (enExample)
JP (2) JP6232544B2 (enExample)
KR (2) KR102301463B1 (enExample)
CN (3) CN111995664B (enExample)
AU (3) AU2012335277B2 (enExample)
BR (2) BR112014011229B1 (enExample)
CA (2) CA3166278A1 (enExample)
DK (1) DK2776567T3 (enExample)
ES (1) ES2874233T3 (enExample)
MX (2) MX353189B (enExample)
PT (1) PT2776567T (enExample)
RU (2) RU2737530C1 (enExample)
WO (1) WO2013068847A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9575055B2 (en) 2009-06-18 2017-02-21 Kiyatec Inc. Co-culture bioreactor system
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
AU2012335277B2 (en) * 2011-11-11 2018-06-14 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013144722A2 (en) * 2012-03-27 2013-10-03 Variation Biotechnologies, Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
SG11201501623PA (en) * 2012-10-30 2015-05-28 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US10273285B2 (en) 2014-06-18 2019-04-30 Morphosys Ag Fusion proteins and uses thereof
KR101678740B1 (ko) * 2014-10-24 2016-11-23 단국대학교 천안캠퍼스 산학협력단 세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
WO2016149426A1 (en) * 2015-03-16 2016-09-22 The Broad Institute, Inc. Constructs for continuous monitoring of live cells
WO2017068077A1 (en) * 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
CA3002922A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
EP3784276A4 (en) * 2018-04-24 2022-03-16 Merck Sharp & Dohme Corp. SCALABLE CHROMATOGRAPHY PROCEDURE FOR PURIFICATION OF HUMAN CYTOMEGALOVIRUS
JP7575096B2 (ja) 2018-05-04 2024-10-29 スパイバイオテック・リミテッド ワクチン組成物
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
KR20220038608A (ko) * 2019-05-31 2022-03-29 배리에이션 바이오테크놀로지스 아이엔씨. 다형성 교모세포종의 치료를 위한 면역치료 조성물
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
GB201910651D0 (en) * 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle
WO2021048081A1 (en) 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
US11857622B2 (en) * 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN115948468A (zh) * 2022-09-09 2023-04-11 青岛大学 一种人巨细胞病毒重组载体及其制备方法和应用
WO2024243675A1 (en) * 2023-06-02 2024-12-05 Variation Biotechnologies Inc. Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128338A2 (en) * 2009-05-08 2010-11-11 Henderson Morley Plc Vaccines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
JPS61103895A (ja) * 1984-10-26 1986-05-22 Green Cross Corp:The ＨＢｓＡｇの精製方法
JP2607712B2 (ja) * 1988-01-29 1997-05-07 カイロン コーポレイション 組換えｃｍｖ中和タンパク
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
DE19856463B4 (de) * 1998-11-26 2006-02-02 Heinrich-Pette-Institut Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
US6413518B1 (en) 1999-09-30 2002-07-02 University Of Washington Immunologically significant herpes simplex virus antigens and methods for identifying and using same
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
PT2311848E (pt) 2002-12-23 2013-10-03 Vical Inc Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
EP2044224A4 (en) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
US20090123494A1 (en) * 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line
WO2009120883A2 (en) * 2008-03-26 2009-10-01 Life Technologies Corporation Virus-like particle mediated cellular delivery
AU2012335277B2 (en) 2011-11-11 2018-06-14 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
WO2015089340A1 (en) 2013-12-11 2015-06-18 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128338A2 (en) * 2009-05-08 2010-11-11 Henderson Morley Plc Vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Expert opinion on biological therapy 1.3: 401-412 (2001. 5.1.)*
Science translational medicine 3.94 94ra71-94ra71 (2011. 8. 3.)*
Science translational medicine,제3권,94호,94ra71,1-8면 (2011.08.) 1부.*

Also Published As

Publication number Publication date
JP2015505299A (ja) 2015-02-19
US20140308308A1 (en) 2014-10-16
EP2776567A4 (en) 2015-12-30
RU2737530C1 (ru) 2020-12-03
US12421283B2 (en) 2025-09-23
EP3854416A1 (en) 2021-07-28
WO2013068847A3 (en) 2014-10-30
AU2012335277B2 (en) 2018-06-14
CN111995664A (zh) 2020-11-27
CN111995664B (zh) 2024-08-02
KR20140095556A (ko) 2014-08-01
AU2020264275A1 (en) 2020-11-26
MX387666B (es) 2025-03-18
CN107875382B (zh) 2024-03-08
US20230272013A1 (en) 2023-08-31
BR122019027913B1 (pt) 2021-11-30
CA2889659A1 (en) 2013-05-16
US20170349634A1 (en) 2017-12-07
ES2874233T3 (es) 2021-11-04
AU2012335277A1 (en) 2014-06-12
BR112014011229A2 (pt) 2017-05-09
JP2018023374A (ja) 2018-02-15
EP2776567B1 (en) 2021-01-20
CN104271745A (zh) 2015-01-07
PT2776567T (pt) 2021-05-25
RU2019139064A (ru) 2020-01-27
US11248026B2 (en) 2022-02-15
KR20190104644A (ko) 2019-09-10
CA3166278A1 (en) 2013-05-16
AU2020264275B2 (en) 2023-12-14
KR102340558B1 (ko) 2021-12-21
WO2013068847A2 (en) 2013-05-16
MX353189B (es) 2018-01-05
EP2776567A2 (en) 2014-09-17
AU2018203538A1 (en) 2018-06-07
US9777043B2 (en) 2017-10-03
CN107875382A (zh) 2018-04-06
DK2776567T3 (da) 2021-04-26
JP6657150B2 (ja) 2020-03-04
MX2014005653A (es) 2014-09-04
JP6232544B2 (ja) 2017-11-22
CA2889659C (en) 2023-03-14
BR112014011229B1 (pt) 2021-10-13

Similar Documents

Publication Publication Date Title
AU2020264275B2 (en) Compositions and methods for treatment of cytomegalovirus
JP2003529559A (ja) 新規用途
KR20160060659A (ko) Hiv 감염증의 rna-유도 치료를 위한 방법 및 조성물
JP2010187681A (ja) ＨＩＶに対する免疫のためのｇｐ１２０と、Ｎｅｆ及び／又はＴａｔを含むワクチン
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
CN110256539B (zh) O型口蹄疫病毒新型基因工程亚单位疫苗
Brown et al. Colocalization of human papillomavirus type 11 E1^ E4 and L1 proteins in human foreskin implants grown in athymic mice
CN111729078B (zh) 鸡传染性贫血病毒基因工程疫苗
JP4411213B2 (ja) ネコ白血病ウィルスによるネコ感染症のようなオンコウィルス感染症に対するワクチン
US11154611B2 (en) Vaccine against bovine leukemia virus
JP2005519959A (ja) Ｈｉｖに対する強化された免疫応答を誘導する方法
CN114729375A (zh) 源自噬菌体t5的纳米颗粒的生产和功能化以及治疗用途
CA2528094A1 (en) Expression vectors for stimulating an immune response to cancer antigens
TWI659966B (zh) 豬第二型環狀病毒之外鞘蛋白質的製備方法及含該外鞘蛋白質的醫藥組合物
AU2012215180A1 (en) Antigenic gly1 polypeptides
US20030118601A1 (en) FIV vaccine
TW201722983A (zh) 豬第二型環狀病毒之外鞘蛋白質的製備方法及含該外鞘蛋白質的醫藥組合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5